Hostname: page-component-84b7d79bbc-fnpn6 Total loading time: 0 Render date: 2024-08-01T06:48:47.718Z Has data issue: false hasContentIssue false
  • English
  • Français

Neurocognitive Manifestations of Human Immunodeficiency Virus

Published online by Cambridge University Press:  07 November 2014

Robert H. Paul ,
Ronald A. Cohen  and
Robert A. Stern
Get access Rights & Permissions [Opens in a new window]

Abstract

Is human immunodeficiency virus still a terminal condition? Recent advances in treatment have significantly reduced both mortality and morbidity associated with HIV, but these treatments have not been successful in eradicating the virus itself. As such, HIV has evolved into a chronic condition that is complicated by neurocognitive factors. Cognitive difficulties associated with HIV are characterized by a subcortical pattern with primary deficits in information processing speed and psychomotor speed. These deficits interfere with the ability of patients to complete important instrumental activities of daily living even in the absence of dementia. Treatment of HIV improves neurocognitive functioning, but the regimens are complex and patient adherence is critical. Cognitive factors can negatively impact treatment adherence, which in turn results in poorer immunological, cognitive, and psychiatric outcome. This cycle emphasizes the important interrelationships between symptom expression and treatment outcome in patients with HIV. The nature of these relationships will change with further developments in treatment regimens such as once-daily dosing. Less complex treatment approaches should improve health outcome as well as provide additional opportunities to further understand the impact of HIV on brain function.

Type
Review
Information
CNS Spectrums , Volume 7 , Issue 12: Investigating Neuropsychiatric Disorders , December 2002 , pp. 860 - 866
Copyright
Copyright © Cambridge University Press 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Gouws, E, Williams, BG, Sheppard, HW, Enge, B, Karim, SA. High incidence of HIV-1 in South Africa using a standardized algorithm for recent HIV seroconversion. J Acquir Immune Defic Syndr. 2002;29:531–535.CrossRefGoogle ScholarPubMed
2.Weinstock, H, Dale, M, Gwinn, M, et al.HIV seroincidence among patients at clinics for sexually transmitted diseases in nine cities in the United States. J Acquir Immune Defic Syndr. 2002;29:478–483.CrossRefGoogle ScholarPubMed
3.Carpenter, CC, Cooper, DA, Fischl, MA, et al.Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2000;283:381–390.CrossRefGoogle ScholarPubMed
4.Krebs, FC, Ross, H, McAllister, , Wigdahl, B. HIV-1-associated central nervous system dysfunction. Adv Pharmacol. 2000;49:315–335.CrossRefGoogle ScholarPubMed
5.Budka, H, Wiley, CA, Kleihues, P. Neuropathology of human immunodeficiency virus infection. Brain Pathol. 1991;1:163–175.CrossRefGoogle ScholarPubMed
6.Price, RW, Brew, B, Sidtis, J, et al.The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science. 1988;239:586–592.CrossRefGoogle ScholarPubMed
7.Lanjewar, DN, Jain, PP, Shetty, CR. Profile of central nervous system pathology in patients with AIDS: an autopsy study from India. AIDS. 1998;12:309–313.CrossRefGoogle ScholarPubMed
8.Vernant, JC, Smadja, D, Deforge-Lasseur, C, et al.Vasculitis and neurologic manifestations related to HTLV-1. Presse Med. 1994;15:1421–1425.Google Scholar
9.McArthur, JC. Neurologic manifestations of human immunodeficiency virus infection. Medicine (Baltimore). 1987;66:407–437CrossRefGoogle Scholar
10.Clifford, DB. Primary neurologic complications of HIV infection. International AIDS Society—U S A. 197;5:4–7.Google Scholar
11.Griffin, DE. Cytokines in the brain during viral infection: clues to HIV-associated dementia. J Clin Invest. 1997;100:2948–2951.CrossRefGoogle ScholarPubMed
12.Merrill, JE, Chen, ISY. HIV-1, macrophages, glial cells, and cytokines in AIDS nervous system disease. FASEB. 1991;5:2391–2397.CrossRefGoogle ScholarPubMed
13.Masliah, E, Heaton, RK, Marcotte, TD, et al.Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. Ann Neurol. 1997;42:963–972.CrossRefGoogle Scholar
14.Everall, IP, Luthert, PJ, Lantos, PL. Neuronal number and volume alterations in the neocortex of HIV infected individuals. J Neurol Neurosurg Psychiatry. 1993;56:481–486.CrossRefGoogle ScholarPubMed
15.Power, C, Kong, PA, Crawford, TO, et al.Cerebral white matter changes in acquired immunodeficiency syndrome dementia: alterations of the blood-brain barrier. Ann Neurol 1993;34:339–350.CrossRefGoogle ScholarPubMed
16.Achim, CL, Wiley, CA. Inflammation in AIDS and the role of the macrophage in brain pathology. Curr Opin Neurol. 1996;9:221–225.CrossRefGoogle ScholarPubMed
17.Spargo, E, Everall, IP, Lantos, PL. Neuronal loss in the hippocampus in Huntington's disease: a comparison with HIV infection. J Neurol Neurosurg Psychiatry. 1993;56:487–491.CrossRefGoogle ScholarPubMed
18.Day, JJ, Grant, I, Atkinson, JH, et al.Incidence of AIDS dementia in a two-year follow-up of AIDS and ARC patients on an initial phase II AZT placebo-controlled study: San Diego cohort. J Neuropsychiatry Clin Neurosci. 1992;4:15–20.Google Scholar
19.Meehan, RA, Brush, JA. An overview of AIDS dementia complex. Am J Alzheimers Dis Other Demen. 2001;16:225–229.CrossRefGoogle ScholarPubMed
20.Stern, FA, Aruda, JE, Sommerville, JA, et al.Neurobehavioral functioning in asymptomatic HIV-1 infected women. J Int Neuropsychol Soc. 1998;4:172–178.CrossRefGoogle ScholarPubMed
21.Wachtel, T, Piette, J, Mor, V, Stein, M, Fleishman, J, Carpenter, C. Quality of life in persons with human immunodeficiency virus infection: measurement by the Medical Outcomes Study instrument. Ann Int Med. 1992;116:129–137.CrossRefGoogle ScholarPubMed
22.Sacktor, NC, Bacellar, H, Hoover, DR, et al.Psychomotor slowing in HIV infection: A predictor of dementia, AIDS and death. J Neurovirol. 1996;2:404–410.CrossRefGoogle ScholarPubMed
23.Stern, RA, Singer, NG, Silva, SG, et al.Neuropsychological functioning in a nonconfounded group of asymptomatic HIV-seropositive homosexual men. Am J Psychiatry 1992;149:1099–1102.Google Scholar
24.Miller, EN, Selnes, OA, McArthur, JC, et al.Neuropsychological performance in HIV-1-infected homosexual men: The Multicenter AIDS Cohort Study (MACS). Neurology. 1990;40:197–203.CrossRefGoogle ScholarPubMed
25.Becker, JT, Sanchez, J, Dew, MA, et al.Neuropsychological abnormalities among HIV-infected individuals in a community-based sample. Neuropsychology. 1997;11:592–601.CrossRefGoogle Scholar
26.Martin, EM, Pitrak, DL, Pursell, KJ, et al.Information processing and antiretroviral therapy in HIV-1 infection. J Int Neuropsychol Soc. 1998;4:329–335.CrossRefGoogle ScholarPubMed
27.Grant, I, Heaton, RK, Atkinson, JH. Neurocognitive disorders in HIV-1 infection. HNRC Group. HIV Neurobehavioral Research Center. Curr Top Microbiol Immunol. 1995;202:11–32.Google Scholar
28.Satz, P, Morgenstern, H, Miller, EN, et al.Low education as a possible risk factor for cognitive abnormalities in HIV-1: findings from the Multicenter AIDS Cohort Study (MACS). J Acquir Immune Defic Syndr. 1993 May;6:503–511.CrossRefGoogle ScholarPubMed
29.Stern, RA, Silva, SG, Chaisson, N, Evans, DL. Influence of cognitive reserve on neuropsychological functioning in asymptomatic human immunodeficiency virus-1 infection. Arch Neurol. 1996;53:148–153.CrossRefGoogle ScholarPubMed
30.Cohen, RA, Boland, R, Paul, R, et al.Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV-infected women. AIDS. 2001;15:341–345.CrossRefGoogle ScholarPubMed
31.McArthur, JC. Neurologic manifestations of human immunodeficiency virus infection. Medicine (Baltimore). 1987;66:407–437.CrossRefGoogle Scholar
32.Paul, R, Cohen, R, Navia, B, Tashima, K. Relationships between cognition and structural neuroimaging in adults with human immunodeficiency virus. Neurosci Bio Beh Rev. In press.Google Scholar
33.Meyerhoff, DJ, Bloomer, C, Cardenas, V, et al.Elevated subcortical choline metabolites in cognitive and clinically asymptomatic HIV+ patients. Neurology. 1999;52:995–1003.CrossRefGoogle ScholarPubMed
34.Ernst, T, Itti, E, Itti, L, Change, L. Changes in cerebral metabolism are detected prior to perfusion changes in early HIV-CMC: A co-registered (1)H MRS and SPECT study. J Magn Reson Imaging. 2000;12:859–865.3.0.CO;2-T>CrossRefGoogle ScholarPubMed
35.Von Giesen, HJ, Wittsack, HJ, Wenserski, F, et al.Basal ganglia metabolite abnormalities in minor motor disorders associated with human immunodeficiency virus type 1. Arch Neurol. 2001;58:1281–1286.CrossRefGoogle ScholarPubMed
36.Hinkin, CH, Van Gorp, WG, Madelkern, MA, et al.Cerebral metabolic change in patients with AIDS: report of a six-month follow-up positron-emission tomography. J Neuropsychiatry Clin Neurosci. 1995;7:180–187.Google Scholar
37.Filippi, CG, Ulug, AM, Ryan, E, Ferrando, SJ, Van Gorp, W. Diffusion tensor imaging of patients with HIV and normal appearing white matter on MR images of the brain. AJNR Am J Neuroradiol. 2001;22:227–283.Google ScholarPubMed
38.Pomara, N, Crandall, DT, Choi, SJ, Johnson, G, Lim, KO. White matter abnormalities in HIV-1 infection: a diffusion tensor imaging study. Psychiatry Res. 2001;106:15–24.CrossRefGoogle ScholarPubMed
39.Wilkie, FL, Goodkin, K, Eisdorfer, C, et al.Mild cognitive impairment and risk of mortality in HIV-1 infection. J. Neuropsychiatry Clin Neurosci 1998;10:125–132.CrossRefGoogle ScholarPubMed
40.Osowiecki, DM, Cohen, RA, Morrow, KM, et al.Neurocognitive and psychological contributions to quality of life in HIV-1-infected women. AIDS. 2000;14:1327–1332.CrossRefGoogle ScholarPubMed
41.Heaton, RK, Marcotte, TD, White, DA, et al.Nature and vocational significance of neuropsychological impairment associated with HIV infection. Clin Neuropsychol. 1996;10:1–14.CrossRefGoogle Scholar
42.Heaton, RK, Velin, RA, McCutchan, JA, et al.Neuropsychological impairment in HIV infection: implications for employment. Psychosom Med. 1994;56:8–17.CrossRefGoogle ScholarPubMed
43.Van Gorp, WG, Baerwald, JP, Ferrando, SJ, McElhiney, MC, Rabkin, JG. The relationship between employment and neuropsychological impairment in HIV infection. J Int Neuropsychol Soc. 1999;5:534–539.CrossRefGoogle ScholarPubMed
44.Marcotte, TD, Heaton, RK, Wolfson, T, et al.The impact of HIV-related neuropsychological dysfunction on driving behavior. J Int Neuropsychol Soc. 1999;5:579–592.CrossRefGoogle ScholarPubMed
45.Holzemer, WL, Corless, IB, Nokes, KM, et al.Predictors of self-reported adherence in persons living with HIV disease. AIDS Patient Care STDs. 1999;13:185–197.CrossRefGoogle ScholarPubMed
46.Chesney, MA, Ickovics, J, Hecht, FM, Sikipa, G, Rabkin, J. Adherence: a necessity for successful HIV combination therapy. AIDS. 1999;13;S271–S278.Google ScholarPubMed
47.Hinkin, C. Cognitive impairment predicts adherence to HAART. Paper presented at: Annual Meeting of the International Neuropsychological Society; February 2001.Google Scholar
48.Avants, SK, Margolin, A, Warburton, LA, Hawkins, KA, Shi, J. Predictors of nonadherence to HIV-related mediation regimens during methadone stabilization. Am J Addict. 2001;10:69–78.CrossRefGoogle Scholar
49.Mann, LS, Westlake, T, Wise, TN, et al.Executive functioning and compliance in HIV patients. Psychol Rep. 1999;84:319–322.CrossRefGoogle ScholarPubMed
50.Atkinson, JH, Grant, I. Mood disorder due to human immunodeficiency virus: Yes, No or Maybe? Sem Clin Neuropsychiatr. 1997;2:276–284.Google ScholarPubMed
51.Penzak, SR, Reddy, S, Grimsley, SR. Depression in patients with HIV infection. Am J Health-Syst Pharm. 2000;57:376–389.CrossRefGoogle ScholarPubMed
52.Perkins, DO, Stern, RA, Golden, RN, et al.Mood disorders in HIV infection: prevalence and risk factors in a nonepicenter of the AIDS epidemic. Am J Psychiatry. 1994;151:233–236.Google Scholar
53.Morrison, MF, Petitto, JM, Have, TT, et all.Depressive and anxiety disorders in women with HIV infection. Am J Psychiatry 2002;159:789–796.CrossRefGoogle ScholarPubMed
54.Hinkin, CH, Castellon, SA, Atkinson, JH, Goodkin, K. Neuropsychiatric aspects of HIV infection among older adults. J Clin Epidemiol. 2001;54:S44–S52.CrossRefGoogle ScholarPubMed
55.Kelly, B, Raphael, B, Judd, F, et al.Psychiatric disorder in HIV infection. Aust N Z J Psychiatry. 1998;32:441–453.CrossRefGoogle ScholarPubMed
56.Lyketsos, CG, Hoover, DR, Guccione, M, et al.Changes in depressive symptoms as AIDS develops. Am J Psychiatry. 1996;153:1430–1437.Google ScholarPubMed
57.Crystal, S, Kersting, RC. Stress, social support, and distress in a statewide population of persons with AIDS in New Jersey. Soc Work Health Care. 1998;28:41–60.CrossRefGoogle Scholar
58.Evans, DL, Leserman, J, Perkins, DO, et al.Severe life stress as a predictor of early disease progression in HIV infection. Am J Psychiatry. 1997;154:630–634.Google ScholarPubMed
59.Leserman, J, Jackson, ED, Petitto, JM, et al.Progression to AIDS: the effects of stress, depressive symptoms, and social support. Psychosom Med. 1999;61:397–406.CrossRefGoogle ScholarPubMed
60.Marin, RS, Firinciogullari, , Biedrzycki, R. The sources of convergence between measures of apathy and depression. J Affect Disord. 1993;28:117–124.CrossRefGoogle ScholarPubMed
61.Rabkin, JG, Ferrando, SJ, Van Gorp, W, et al.Relationships among apathy, depression, and cognitive impairment in HIV/AIDS. J Neuropsychiatry Clin Neurosci. 2000;12:451–457.CrossRefGoogle ScholarPubMed
62.Levy, ML, Cummings, JL, Fairbanks, LA, et al.Apathy is not depression. J Neuropsychiatry Clin Neurosci. 1998;10:314–319.CrossRefGoogle Scholar
63.Castellon, SA, Hinkin, CH, Wood, S, Yarema, KT. Apathy, depression, and cognitive performance in HIV-1 infection. J Neuropsychiatry Clin Neurosci. 1998;10:320–329.CrossRefGoogle ScholarPubMed
64.Goggin, KJ, Zisook, S, Heaton, RK, et al.Neuropsychological performance of HIV-1 infected men with major depression. HNRC Group. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc. 1997;3:457–464CrossRefGoogle Scholar
65.Andersson, S, Krogstad, JM, Finset, A. Apathy and depressed mood in acquired brain damage: relationship to lesion localization and psychophysiological reactivity. Psychol Med. 1999;29:447–456.CrossRefGoogle ScholarPubMed
66.Rabkin, JG, Wagner, G, Rabkin, R. Effects of imipramine on mood and enumerative measures of immune status in depressed patients with HIV illness. Am J Psychiatry. 1994;151:516–523.Google ScholarPubMed
67.El Mallakh, RS. AIDS dementia-related psychosis: is there a window of vulnerability? AIDS Care. 1992;4:381–387.CrossRefGoogle Scholar
68.Ferrando, SJ, Goldman, JD, Charness, WE. Selective serotonin reuptake inhibitor treatment of depression in symptomatic HIV infection and AIDS. Gen Hosp Psychiatry. 1997;19:89–97.CrossRefGoogle ScholarPubMed
69.Low-Beer, S, Chan, K, Yip, B, et al.Depressive symptoms decline among persons on HIV protease inhibitors. J Acquir Immune Defic Syndr. 2000;23;295–301.CrossRefGoogle ScholarPubMed
70.Judd, FK, Cockram, AM, Komiti, A, et al.Depressive symptoms reduced in individuals with HIV/AIDS treated with highly active antiretroviral therapy: a longitudinal study. Aust N Z J Psychiatry. 2000;34:1015–1021.CrossRefGoogle ScholarPubMed
71.Miller, V, Sabin, C, Phillips, AN, et al.The impact of protease inhibitor containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load. AIDS. 2000;14:2129–2136.CrossRefGoogle ScholarPubMed
72.Andre, P, Groettrup, M, Klenerman, P, et al.An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci U S A. 1998;95:13120–13124.CrossRefGoogle ScholarPubMed
73.Ferrando, S, Van Gorp, W, McElhiney, M, et al.Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function. AIDS. 1998;28:F65–F70.CrossRefGoogle Scholar
74.Tozzi, Balestra P, Galgani, S, Narciso, P, et al.Positive and sustained effects of highly active antiretroviral therapy on HIV-1 associated neurocognitive impairment. AIDS. 1999;13:1889–1897.CrossRefGoogle ScholarPubMed
75.Condra, JH, Schleif, WA, Blahy, OM, et al.In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 1995;374:569–571.CrossRefGoogle ScholarPubMed
76.Roberts, NA. Drug resistance patterns of saquinavir and other protease inhibitors. AIDS. 1995;9:S27–S32.Google Scholar